Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00707889 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

A Phase 2 study of Adenocarcinoma of the Rectum and Advanced Colorectal Cancer, sponsored by AbbVie (prior sponsor, Abbott).

Completed
Registry status
Phase 2
Development phase
159
Enrollment target
20
Study locations

NCT00707889 is a Phase 2 study of Adenocarcinoma of the Rectum and Advanced Colorectal Cancer that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 159 participants, below the 897-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00707889, a Phase 2 study of Adenocarcinoma of the Rectum and Advanced Colorectal Cancer, has completed, sponsored by AbbVie (prior sponsor, Abbott).

COMPLETED
Registry status
Phase 2
Development phase
159 participants
Enrollment target
20
Study locations

Study Summary

To determine the effect of ABT-869 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 on disease progression in advanced colorectal cancer.

Conditions Studied

Adenocarcinoma of the Rectum Advanced Colorectal Cancer Adenocarcinoma of the Colon

Interventions

  • DRUG bevacizumab
  • DRUG oxaliplatin
  • DRUG fluorouracil
  • DRUG folinic acid
  • DRUG ABT-869

Study Locations (20)

Other

  • Site Reference ID/Investigator# 18581 - Bedford Park
  • Site Reference ID/Investigator# 23443 - Herston
  • Site Reference ID/Investigator# 18023 - Bonheiden
  • Site Reference ID/Investigator# 23646 - Brussels
  • Site Reference ID/Investigator# 18026 - Leuven
  • Site Reference ID/Investigator# 18022 - Roeselare
  • Site Reference ID/Investigator# 26662 - Jaú
  • Site Reference ID/Investigator# 24245 - Porto Alegre
  • Site Reference ID/Investigator# 23265 - Barrie
  • Site Reference ID/Investigator# 21083 - Edmonton
  • Site Reference ID/Investigator# 22465 - Ottawa
  • Site Reference ID/Investigator# 22141 - Náchod
  • Site Reference ID/Investigator# 22289 - Heraklion
  • Site Reference ID/Investigator# 22286 - Thessaloniki
  • Site Reference ID/Investigator# 22287 - Thessaloniki
  • Site Reference ID/Investigator# 20281 - Wellington South
  • Site Reference ID/Investigator# 20141 - Olsztyn

North Carolina

  • Site Reference ID/Investigator# 11341 - Chapel Hill

Pennsylvania

  • Site Reference ID/Investigator# 20801 - Philadelphia

Tennessee

  • Site Reference ID/Investigator# 8360 - Nashville

Trial Details

FieldValue
Enrollment Target 159 participants
Start Date 2008-10
Est. Completion 2012-05
Phase Phase 2

Sponsor

AbbVie (prior sponsor, Abbott)

88 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00707889

The ClinicalTrials.gov registry entry for NCT00707889 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 897-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (82% lower). The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Adenocarcinoma of the Rectum appearing as the primary indexed condition, and to 5 interventions - of which bevacizumab is the first listed.

NCT00707889 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, North Carolina, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00707889 about?

NCT00707889 is a clinical study titled "Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer". To determine the effect of ABT-869 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 on disease progression in advanced colorectal cancer.

What is the current status of trial NCT00707889?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2008-10. Estimated completion is 2012-05.

What conditions does trial NCT00707889 study?

This clinical trial studies the following conditions: Adenocarcinoma of the Rectum, Advanced Colorectal Cancer, Adenocarcinoma of the Colon.

What interventions are being tested in trial NCT00707889?

The interventions under investigation include: bevacizumab (DRUG), oxaliplatin (DRUG), fluorouracil (DRUG), folinic acid (DRUG), ABT-869 (DRUG).

Who is sponsoring clinical trial NCT00707889?

This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00707889 being conducted?

This trial has 20 study locations across North Carolina, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Adenocarcinoma of the Rectum

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Adenocarcinoma of the Rectum

All registered trials for this condition

Advanced Colorectal Cancer

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.